Dr. Negulescu received both his B.S. and Ph.D. from U.C. Berkeley in Physiology and carried out post-doctoral work at U.C. Berkeley and U.C. Irvine in the areas of epithelial biology, biophysics and immunology.
Following post-doctoral work, Paul joined Aurora Biosciences, a San Diego Company whose founders included Roger Tsien, in 1996. Paul joined as one of the first employees and grew with the Company to become Senior Vice President of Discovery Biology. Paul began working on cystic fibrosis while at Aurora and played an important role in establishing the foundation of a more than 20-year journey in CF research and drug discovery.
When Vertex acquired Aurora in 2001, Paul was responsible for integrating Aurora’s research into Vertex, including transitioning the CF Program to Vertex. Since 2003, Paul has led the Vertex San Diego research site. During that time the San Diego team has discovered over 10 novel compounds, including the first CFTR modulators to enter clinical development. Three of these compounds, ivacaftor, lumacaftor and tezacaftor are the only approved medicines to treat the underlying cause of cystic fibrosis. Additional compounds are currently in clinical development that could treat up to 90% of people with CF.